MedTrace Logo

A Phase 1 Study of YZJ-5053 Tablets in Participants With Advanced Solid Tumors

NCT06209385 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 157

Last updated 2024-01-17

No results posted yet for this study

Summary

The goal of this study is to evaluate Safety, Tolerability, Pharmacokinetics and Efficacy of YZJ-5053 Tablets in Participants with Advanced Solid Tumors

Conditions

Interventions

DRUG

YZJ-5053 tablets

YZJ-5053 tablets will be administrated orally QD for 21 days

Sponsors & Collaborators

  • Shanghai Haiyan Pharmaceutical Technology Co., Ltd.

    lead INDUSTRY

Principal Investigators

  • Jin Li · Shanghai East Hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-08-11
Primary Completion
2027-10-31
Completion
2028-01-31

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06209385 on ClinicalTrials.gov